InsiderTrades

Form 4 for VRTX Vertex Pharmaceuticals

Accepted 2022-05-03 00:00:00 ET · period of report 2022-05-01 · accession 0000899243-22-016338 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-05-03 2022-05-01 VRTX MCKENZIE DIANA Dir A - Grant $0.00 +1,449 2,884 +101% $0
D 2022-05-03 2022-05-01 VRTX MCKENZIE DIANA Dir D - Sale to Iss — -1,842 1,435 -56% —
D 2022-05-03 2022-05-01 VRTX MCKENZIE DIANA Dir A - Grant — +1,842 2,731 +207% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-05-01 A A 1,449 $0.00 2,884 D — — (F3) Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
2 Common Common Stock 2022-05-01 D D 1,842 — 1,435 D — — (F1) Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2021, Ms. McKenzie deferred the receipt of 1,842 shares of common stock and received instead 1,842 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,842 shares of common stock in exchange for an equal number of deferred stock units.
3 Derivative Deferred Stock Units 2022-05-01 A A 1,842 — 2,730.69 D — · — to — 1,842 Common Stock (F1) Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2021, Ms. McKenzie deferred the receipt of 1,842 shares of common stock and received instead 1,842 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,842 shares of common stock in exchange for an equal number of deferred stock units. (F2) Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death.